Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial

Charles S. Fuchs*, Toshihiko Doi, Raymond W. Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I. Jalal, Manish A. Shah, Jean Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V. Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. KoGeoffrey Ku, Philip Philip, Peter C. Enzinger, Yung Jue Bang, Diane Levitan, Jiangdian Wang, Minori Rosales, Rita P. Dalal, Harry H. Yoon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1343 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences